Show simple item record

Selective thromboxane inhibition: a new approach to antiplatelet therapy

dc.contributor.authorFisher, Marc
dc.contributor.authorWeiner, Bonnie H.
dc.contributor.authorOckene, Ira S.
dc.contributor.authorHoogasian, James S.
dc.contributor.authorNatale, Anita M.
dc.contributor.authorArsenault, John R.
dc.contributor.authorJohnson, Mark H.
dc.contributor.authorLevine, Peter H.
dc.date2022-08-11T08:09:28.000
dc.date.accessioned2022-08-23T16:31:59Z
dc.date.available2022-08-23T16:31:59Z
dc.date.issued1984-09-01
dc.date.submitted2008-04-07
dc.identifier.citationStroke. 1984 Sep-Oct;15(5):813-6.
dc.identifier.issn0039-2499 (Print)
dc.identifier.pmid6474531
dc.identifier.urihttp://hdl.handle.net/20.500.14038/37782
dc.description.abstractAntiplatelet drugs as exemplified by aspirin are used frequently to prevent stroke. Aspirin inhibits the formation of both the potent platelet aggregator, thromboxane A2 and the potent anti-aggregator, prostacyclin. Another approach to the inhibition of platelet aggregation might involve selective suppression of thromboxane formation. We report our experience in swine with UK-38,485, a drug which selectively inhibits thromboxane formation. The rationale and potential uses of UK-38,485 in the in vivo prevention of platelet aggregation and for the therapy of cerebrovascular disease are discussed.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6474531&dopt=Abstract ">Link to article in PubMed</a>
dc.relation.urlhttp://stroke.ahajournals.org/content/15/5/813.long
dc.subjectAnimals
dc.subjectCerebrovascular Disorders
dc.subjectImidazoles
dc.subjectMale
dc.subjectPlatelet Aggregation
dc.subjectSwine
dc.subjectThromboxane B2
dc.subjectThromboxanes
dc.subjectMedicinal and Pharmaceutical Chemistry
dc.subjectNeurology
dc.subjectPharmacy and Pharmaceutical Sciences
dc.titleSelective thromboxane inhibition: a new approach to antiplatelet therapy
dc.typeJournal Article
dc.source.journaltitleStroke; a journal of cerebral circulation
dc.source.volume15
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/neuro_pp/49
dc.identifier.contextkey483337
html.description.abstract<p>Antiplatelet drugs as exemplified by aspirin are used frequently to prevent stroke. Aspirin inhibits the formation of both the potent platelet aggregator, thromboxane A2 and the potent anti-aggregator, prostacyclin. Another approach to the inhibition of platelet aggregation might involve selective suppression of thromboxane formation. We report our experience in swine with UK-38,485, a drug which selectively inhibits thromboxane formation. The rationale and potential uses of UK-38,485 in the in vivo prevention of platelet aggregation and for the therapy of cerebrovascular disease are discussed.</p>
dc.identifier.submissionpathneuro_pp/49
dc.contributor.departmentDepartment of Medicine, Division of Cardiovascular Medicine
dc.contributor.departmentDepartment of Neurology
dc.source.pages813-6


This item appears in the following Collection(s)

Show simple item record